kabutan

StemRIM(4599) Summary

4599
TSE Growth
StemRIM
296
JPY
-3
(-1.00%)
Mar 13, 3:30 pm JST
1.85
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
299
Mar 13, 10:23 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.65
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
291 JPY 1.82 USD
Previous Close Mar 12
299 JPY 1.88 USD
High Mar 13, 2:05 pm
300 JPY 1.88 USD
Low Mar 13, 9:00 am
291 JPY 1.82 USD
Volume
149,300
Trading Value
0.04B JPY 0.28M USD
VWAP
294.6 JPY 1.85 USD
Minimum Trading Value
29,600 JPY 185 USD
Market Cap
0.02T JPY 0.12B USD
Number of Trades
184
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Mid
1-Year Average
238
1-Year High Apr 4, 2025
1,107
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 2,899,000
Feb 27, 2026 0 2,962,800
Feb 20, 2026 0 2,978,700
Feb 13, 2026 0 2,858,600
Feb 6, 2026 3,900 2,896,400 742.67
Company Profile
StemRIM is a biotech venture originating from Osaka University, developing "regeneration-inducing medicine" that promotes self-tissue regeneration.
Sector
Pharmaceuticals
StemRIM is a research and development-based pharmaceutical venture founded at Osaka University. The company is engaged in the research and development of its proprietary "regeneration-inducing medicine" that promotes self-tissue regeneration and healing. This technology aims to achieve effects equivalent to regenerative medicine without using living cells, instead activating patients' own internal stem cells through compound administration to function broadly against various diseases. The company's lead pipeline product, redasemtide, is currently undergoing clinical trials for epidermolysis bullosa and acute cerebral infarction. Additionally, StemRIM is advancing research and development in a wide range of regeneration-inducing medical technologies, including novel peptides for systemic and local administration, therapeutic autologous cell collection devices, and stem cell gene therapy. Through these technologies, StemRIM aims to overcome the challenges of conventional regenerative medicine and realize safer and more effective treatment methods.